title: Radiation-sparing managements for cervical cancer: a developing countries perspective.
abstract: Cervical cancer is the seventh most frequent cancer worldwide but more than 80% of cases occur in developing countries. Till date, radiation therapy with external beam and brachytherapy remains as the core treatment for most stages of cervical cancer. However, radiation treatment protocols and equipment modelled on the best developed countries can be seldom applied directly to developing countries owing to financial constraints and lack of qualified personnel, thus, a substantial proportion of patients do not have access to even palliative radiation therapy. Treatment options when the standard therapy is either not available or difficult to reproduce in particular settings is highly desirable with the potential to save lives that otherwise could be lost by the lack of adequate treatment. These options of treatment ideally had to have show, 1) that these are not inferior to the "standard" in terms of either survival or quality of life; 2) that these can be delivered in settings were the "standard" is not available or if available its quality is poor; and 3) that the treatment option be accepted by the population to be treated. Based on these considerations, it is obvious that cervical cancer patients, particularly those who live in countries with limited resources and therefore may not have sufficient radiation therapy resources are in need of newer therapeutical options. There is now a considerable amount of information emanating from clinical studies where surgery has a major role in treating this disease. These forms of "radiation-sparing" treatments include total mesometrial resection that could make unnecessary the use of adjuvant radiation; neoadjuvant chemotherapy that could avoid the use of adjuvant radiation in around 85% of patients and preoperative chemoradiation that could make brachytherapy dispensable. The feasibility and therapeutical value of these potential forms of management need to be prospectively evaluated.
authors.affiliation: Division of Clinical Research, Instituto Nacional de Cancerología. Mexico City, Mexico. myrnac@prodigy.net.mx
authors.forename: Myrna
authors.initials: M
authors.lastname: Candelaria
authors.forename: Lucely
authors.initials: L
authors.lastname: Cetina
authors.forename: Alicia
authors.initials: A
authors.lastname: Garcia-Arias
authors.forename: Carlos
authors.initials: C
authors.lastname: Lopez-Graniel
authors.forename: Jaime
authors.initials: J
authors.lastname: de la Garza
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Robles
authors.forename: Alfonso
authors.initials: A
authors.lastname: Duenas-Gonzalez